



Universiteit  
Leiden  
The Netherlands

## **Modulation of leukocyte homeostasis in atherosclerosis**

Medina Rodriguez, I.A.

### **Citation**

Medina Rodriguez, I. A. (2014, May 13). *Modulation of leukocyte homeostasis in atherosclerosis*. Retrieved from <https://hdl.handle.net/1887/25765>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/25765>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/25765> holds various files of this Leiden University dissertation.

**Author:** Medina Rodriguez, Indira A.

**Title:** Modulation of leukocyte homeostasis in atherosclerosis

**Issue Date:** 2014-05-13

# **Modulation of Leukocyte Homeostasis in Atherosclerosis**

Layout:	Indira Medina
Cover Design:	Indira Medina
Printed by:	Wöhrmann Print Service
ISBN:	978-94-6203-562-1
©Indira Medina	

# Modulation of Leukocyte Homeostasis in Atherosclerosis

Proefschrift  
ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,  
volgens besluit van het College voor Promoties  
te verdedigen op dinsdag 13 Mei, 2014  
klokke 15.00 uur

door:

**Indira A. Medina R.**

geboren te Bogota  
in 1976

Promotiecommissie

Promotores:

Prof. Dr. E.A.L. Biessen  
Prof. Dr. Th.J.C. van Berkel

Referent:

Prof. Dr. D.M. Schrijvers

Overige leden:

Prof. Dr. P.H. van der Graaf  
Prof. Dr. J. Kuiper  
Prof. Dr. B. van de Water  
Dr. E.P. van der Veer

The studies presented in this thesis were supported by a grant of the Netherlands Heart Foundation (D2003T201, EB, SdJ) and were mostly performed in the Division of Biopharmaceutics of the Leiden-Amsterdam Center of Drug Research and the Academic Hospital of the University of Maastricht, the Netherlands.

To the Memory of Toto and Johanniek.  
Dedicated to Sofia and Giovanni.





# Contents

<b>1</b>	<b>Introduction</b>	<b>1</b>
1.1	Atherosclerosis: Mortality, Morbidity and Costs . . . . .	1
1.2	Atherosclerosis: Onset and Development . . . . .	1
1.3	Altered Leukocyte Homeostasis in Atherosclerosis . . . . .	2
1.4	Vascular Remodeling and Atherosclerotic Lesion Destabilization . . . . .	4
1.5	Macrophage Apoptosis and Lesion Destabilization . . . . .	4
1.6	Myelocyte Differentiation as Determinant of Lesion Stability . . . . .	8
1.7	Thesis Outline . . . . .	9
<b>2</b>	<b>Janus role of Hck and Fgr in atherosclerosis progression and stability</b>	<b>17</b>
2.1	Abstract . . . . .	17
2.2	Introduction . . . . .	18
2.3	Materials and Methods . . . . .	18
2.4	Results . . . . .	25
2.5	Discussion . . . . .	40
<b>3</b>	<b>Hematopoietic NAMPT Over-Expression Attenuates Atherosclerosis</b>	<b>47</b>
3.1	Abstract . . . . .	47
3.2	Introduction . . . . .	48
3.3	Materials and Methods: . . . . .	49
3.4	Results . . . . .	53
3.5	Discussion . . . . .	62
<b>4</b>	<b>CD169<sup>+</sup> Macrophage Ablation Stabilizes Atherosclerotic Lesions in LDLr<sup>-/-</sup> Mice</b>	<b>69</b>
4.1	Abstract . . . . .	69
4.2	Introduction . . . . .	70
4.3	Methods . . . . .	71
4.4	Results . . . . .	73
4.5	Discussion . . . . .	78
<b>5</b>	<b>Systemic, but not Local Induction of CD115<sup>+</sup> Macrophage Apoptosis Promotes Atherosclerotic Lesion Vulnerability in ApoE<sup>-/-</sup> Mice</b>	<b>87</b>

5.1	Abstract . . . . .	87
5.2	Introduction . . . . .	88
5.3	Methods . . . . .	89
5.4	Results . . . . .	93
5.5	Discussion . . . . .	103
<b>6</b>	<b>General Conclusions</b>	<b>109</b>
6.1	Modulation of Monocyte Migration and Macrophage Differentiation in Atherosclerosis . . . . .	109
6.2	Induction of Macrophage Apoptosis and Its Effect on Atherosclerosis	112
6.3	Concluding Remarks and Future Perspectives . . . . .	114
<b>A</b>	<b>Supplemental Data.</b> <b>Janus Role of Hck and Fgr in Atherosclerosis Progression and Stability</b>	<b>117</b>
<b>B</b>	<b>Supplemental Data.</b> <b>Hematopoietic NAMPT Over-Expression Attenuates Atherosclerosis</b>	<b>127</b>
<b>C</b>	<b>Supplemental Data.</b> <b>CD169<sup>+</sup> Macrophage Ablation Stabilizes Atherosclerotic Lesions in LDLr<sup>-/-</sup> Mice</b>	<b>133</b>
<b>D</b>	<b>Supplemental Data.</b> <b>Characterization of ApoE<sup>-/-</sup> MaFIA<sup>+/+</sup> Mice, for Induction of CD115<sup>+</sup> Macrophage Apoptosis</b>	<b>137</b>
<b>E</b>	<b>Supplemental Data.</b> <b>Systemic, but not Local Induction of CD115<sup>+</sup> Macrophage Apoptosis Promotes Atherosclerotic Lesion Vulnerability in ApoE<sup>-/-</sup> Mice</b>	<b>147</b>
	<b>Acronyms and Abbreviations</b>	<b>153</b>
	<b>Index</b>	<b>159</b>
	<b>Bibliography</b>	<b>165</b>
	<b>Abstract</b>	<b>197</b>
	<b>Samenvatting</b>	<b>199</b>
	<b>Author's Biography</b>	<b>201</b>
	<b>Acknowledgments</b>	<b>203</b>

# List of Figures

1.1	Leukocyte extravasation in atherosclerosis. . . . .	2
1.2	Atherosclerosis onset. . . . .	5
1.3	Progression of Atherosclerosis. . . . .	6
1.4	Atherosclerotic Lesion Rupture. . . . .	7
1.5	The ratio of proinflammatory and tissue repairing macrophages is a key determinant of atherosclerotic lesion stability. . . . .	10
2.1	Reduced lesion size and myeloid cell accumulation in dKO Hck/Fgr chimeras. . . . .	26
2.2	Impaired adhesion to the endothelium and transmigration of Hck/Fgr dKO circulatory leukocytes. . . . .	28
2.3	Hck/Fgr deficiency causes reduced accumulation of newly recruited Ly6c <sup>+</sup> monocytes in atherosclerotic lesions. . . . .	29
2.4	Impaired adhesion to the endothelium and transmigration of Hck/Fgr dKO macrophages. . . . .	31
2.5	Hck/Fgr dKO macrophages display impaired two dimensional directional migration and aberrant morphology. . . . .	32
2.6	Assessment of three-dimensional migration in Hck/Fgr deficiency. . . . .	33
2.7	Atherosclerotic lesion composition in Hck/Fgr dKO atherosclerotic chimeras. . . . .	34
2.8	Conditioned medium from Hck/Fgr dKO BMDM attenuates VSMC collagen deposition. . . . .	35
2.9	Transcriptome analysis of gene expression in human macrophages stimulated with IFN $\gamma$ , IL-17, IL-4, LPS, IFN $\gamma$ +LPS and TNF $\alpha$ . . . . .	36
2.10	Transcription factors that control the expression of genes upregulated upon IL-4 stimulation. . . . .	37
2.11	Transcription factors that control the expression of genes upregulated upon IFN $\gamma$ stimulation. . . . .	38
2.12	Euler diagram of gene networks expanded from Clusters I-V. . . . .	39
2.13	First neighbors of FGR and HCK, in network N-III. . . . .	40
2.14	First neighbors of HCK, in network N-IV. . . . .	41
3.1	Expression of NAMPT in PBMC and atherosclerotic plaques from patients with Cardiovascular Disease; and bone marrow cells from LDLr <sup>-/-</sup> mice recipients of bone marrow cells transfected with lentivirus encoding iNAMPT. . . . .	54

3.2	Hematopoietic iNAMPT over expression attenuates atherosclerotic lesion development in LDLr <sup>-/-</sup> mice. . . . .	55
3.3	Hematopoietic iNAMPT over expression modulates the survival of myeloid cells and increases medullar myelopoiesis. . . . .	56
3.4	Hematopoietic iNAMPT over expression perturbs stromal and circulatory leukocyte homeostasis in LDLr <sup>-/-</sup> mice. . . . .	58
3.5	Hematopoietic iNAMPT over-expression impairs the migratory response of BMDM via PPAR $\gamma$ and upregulates the expression of SIRT1 and PPAR $\gamma$ . . . . .	59
3.6	Hematopoietic iNAMPT over expression favors BMDM alternative anti-inflammatory differentiation. . . . .	60
3.7	iNAMPT modulate lipid homeostasis in macrophages via PPAR $\gamma$ . . . . .	61
4.1	Lesion expansion, higher necrosis and macrophage apoptosis, upon induction of CD169 <sup>+</sup> macrophage apoptosis in atherosclerotic mice. . . . .	75
4.2	Lesion phenotype at baseline, upon induction of CD169 <sup>+</sup> macrophage apoptosis. . . . .	76
4.3	Plasma cytokine levels at baseline and after recovery from induction of CD169 <sup>+</sup> Macrophage apoptosis in atherosclerotic mice. . . . .	77
4.4	Effect of induction of CD169 <sup>+</sup> cell apoptosis on blood leukocyte homeostasis. . . . .	78
4.5	Effect of induction of CD169 <sup>+</sup> cell apoptosis on spleen leukocyte homeostasis. . . . .	79
4.6	Lesion size, necrotic core and macrophage apoptosis, upon recovery from induction of CD169 <sup>+</sup> macrophage apoptosis in atherosclerotic mice. . . . .	80
4.7	Features of lesion stability after recovery from induction of CD169 <sup>+</sup> macrophage apoptosis in atherosclerotic mice. . . . .	81
5.1	Experimental setup for systemic and local induction of CD115 <sup>+</sup> cell apoptosis in atherosclerotic ApoE <sup>-/-</sup> MaFIA <sup>+/+</sup> mice. . . . .	91
5.2	Local induction of CD115 <sup>+</sup> macrophage apoptosis causes advanced atherosclerotic lesion expansion. . . . .	95
5.3	Effects of local induction of CD115 <sup>+</sup> macrophage apoptosis on advanced atherosclerotic lesion phenotype. . . . .	96
5.4	Systemic induction of CD115 <sup>+</sup> macrophage apoptosis causes advanced atherosclerotic lesion vulnerability. . . . .	97
5.5	Effects of systemic induction of CD115 <sup>+</sup> macrophage apoptosis on advanced atherosclerotic lesion phenotype. . . . .	98
5.6	Blood leukocyte homeostasis upon local and systemic induction of CD115 <sup>+</sup> myelocyte apoptosis in advanced atherosclerosis. . . . .	99
5.7	Spleen leukocyte homeostasis upon local and systemic induction of CD115 <sup>+</sup> myelocyte apoptosis in advanced atherosclerosis. . . . .	100
5.8	Spleen myelocytosis is observed upon systemic induction of CD115 <sup>+</sup> myelocyte apoptosis in ApoE <sup>-/-</sup> MaFIA <sup>+/+</sup> mice fed WTD during three weeks. . . . .	102

5.9	Bone leukocyte homeostasis upon systemic induction of CD115 <sup>+</sup> myelocyte apoptosis, in ApoE <sup>-/-</sup> MaFIA <sup>+/+</sup> mice fed WTD during three weeks. . . . .	104
A.1	Plasma cytokine levels are not altered in Hck/Fgr dKO chimeras. . . . .	119
A.2	FACS analysis of leukocytes in aortas of Hck/Fgr dKO, LDLr <sup>-/-</sup> atherosclerotic mice. . . . .	119
A.3	Reduced thioglycolate induced peritonitis in Hck/Fgr deficient mice. . . . .	120
A.4	Correlation analysis of atherosclerotic lesion composition in Hck/Fgr dKO, LDLr <sup>-/-</sup> mice chimeras. . . . .	121
A.5	Atherosclerotic Hck/Fgr dKO, LDLr <sup>-/-</sup> chimeric mice display blood Ly6c <sup>hi</sup> monocytosis. . . . .	122
A.6	Cellular responses displayed by Hck/Fgr dKO macrophages <i>in-vitro</i> . . . . .	123
A.7	Differential expression of genes upregulated in response to IL-4. . . . .	124
A.8	Differential expression of genes upregulated in response to IFN $\gamma$ . . . . .	124
A.9	The chemokine receptor pathway is over-represented by HCK, FGR and their common interactors. . . . .	125
A.10	Expression of HCK and FGR in human atherosclerotic lesions. . . . .	126
B1	Over expression of NAMPT has no influence on body weight and plasma lipid levels. . . . .	129
B2	Over expression of NAMPT has no effect on granulocyte and lymphocyte levels as well as SMC and collagen content in atherosclerotic lesions obtained from LV.iNAMPT <sup>hi</sup> and LV.CTR chimeric LDLr <sup>-/-</sup> mice. . . . .	130
B3	Reduced stromal monocyte content and increased circulatory monocyte levels in response to intraperitoneal NAMPT inhibitor (FK866) challenge. . . . .	130
B4	Leukocyte NAMPT over expression has no influence on plasma cytokine and NAMPT levels, in atherosclerotic mice. . . . .	131
B5	iNAMPT and PPAR $\gamma$ expression correlate in human atherosclerotic plaques, but not in healthy arteries. . . . .	131
C1	Effect of induction of CD169 <sup>+</sup> cell apoptosis on bone marrow leukocyte homeostasis. . . . .	135
D1	Expression of MaFIA in bone marrow, blood and peritoneal leukocytes of ApoE <sup>-/-</sup> MaFIA <sup>+/+</sup> mice. . . . .	140
D2	Induction of CD115 <sup>+</sup> macrophage apoptosis in MaFIA <sup>+/+</sup> PEM <i>in-vitro</i> . . . . .	142
D3	Systemic induction and recovery from ablation of CD115 <sup>+</sup> myelocyte apoptosis in ApoE <sup>-/-</sup> MaFIA <sup>+/+</sup> mice. . . . .	143
D4	Relative levels of blood myelocytes upon systemic induction of CD115 <sup>+</sup> myelocyte apoptosis in ApoE <sup>-/-</sup> MaFIA <sup>+/+</sup> mice, fed WTD during three weeks. . . . .	144
D5	Absolute blood leukocyte counts upon systemic induction of CD115 <sup>+</sup> myelocyte apoptosis in ApoE <sup>-/-</sup> MaFIA <sup>+/+</sup> mice fed WTD during three weeks. . . . .	145

---

E1	Plasma cholesterol levels in ApoE <sup>-/-</sup> MaFIA <sup>+/+</sup> mice. . . . .	149
E2	Advanced atherosclerotic lesion phenotype five weeks after perivascular collar placement and 1 day before induction of CD115 <sup>+</sup> cell apoptosis by administration of AP20187. . . . .	150
E3	Advanced atherosclerotic lesion composition five weeks after perivascular collar placement and 1 day before induction of CD115 <sup>+</sup> cell apoptosis by administration of AP20187. . . . .	151
E4	Peritoneal leukocyte homeostasis upon systemic induction of CD115 <sup>+</sup> myelocyte apoptosis in ApoE <sup>-/-</sup> MaFIA <sup>+/+</sup> mice fed WTD during three weeks. . . . .	152

# List of Tables

2.1	Primers Used for M1/M2 polarization in Hck/Fgr deficient BMDM.	23
3.1	Primers used for macrophage polarization in iNAMPT over expressing BMDM. . . . .	51
4.1	Plasma Cholesterol in CD169-DTR-LDLr <sup>-/-</sup> chimeric mice . . . .	74
D.1	GFP mean fluorescence intensity values in ApoE <sup>-/-</sup> MaFIA <sup>+/+</sup> leukocytes. . . . .	141

